209 related articles for article (PubMed ID: 9449263)
1. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.
Zinner SH; Gilbert D; Dudley MN
Antimicrob Agents Chemother; 1998 Jan; 42(1):72-7. PubMed ID: 9449263
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci.
Schick DG; Canawati HN; Montgomerie JZ
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):233-9. PubMed ID: 9458980
[TBL] [Abstract][Full Text] [Related]
3. Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
Aeschlimann JR; Hershberger E; Rybak MJ
Antimicrob Agents Chemother; 2000 May; 44(5):1153-8. PubMed ID: 10770744
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Giamarellos-Bourboulis EJ; Sambatakou H; Grecka P; Giamarellou H
Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):657-61. PubMed ID: 9832270
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of trovafloxacin against Bacteroides fragilis in mixed culture with either Escherichia coli or a vancomycin- resistant strain of Enterococcus faecium determined by an anaerobic time-kill technique.
Stearne LE; Kooi C; Goessens WH; Bakker-Woudenberg IA; Gyssens IC
Antimicrob Agents Chemother; 2001 Jan; 45(1):243-51. PubMed ID: 11120973
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ampicillin-sulbactam with vancomycin for treatment of experimental endocarditis due to a beta-lactamase-producing, highly gentamicin-resistant isolate of Enterococcus faecalis.
Lavoie SR; Wong ES; Coudron PE; Williams DS; Markowitz SM
Antimicrob Agents Chemother; 1993 Jul; 37(7):1447-51. PubMed ID: 8363374
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility patterns of enterococci causing infections.
Oncu S; Punar M; Eraksoy H
Tohoku J Exp Med; 2004 Jan; 202(1):23-9. PubMed ID: 14738321
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin.
Bonilla HF; Zarins LT; Bradley SF; Kauffman CA
Diagn Microbiol Infect Dis; 1996 Sep; 26(1):17-21. PubMed ID: 8950524
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial-resistant enterococcal isolates from fluoroquinolone-naive children.
McNeeley DF; Eckert SJ; Noel GJ
Pediatr Infect Dis J; 2000 Jul; 19(7):675-6. PubMed ID: 10917238
[No Abstract] [Full Text] [Related]
12. In vitro activity of RPR 106972 alone and in combination with vancomycin, ampicillin, and gentamicin against multidrug-resistant enterococci.
Messick CR; Woodward J; Pendland SL
Diagn Microbiol Infect Dis; 1998 Oct; 32(2):95-9. PubMed ID: 9823531
[TBL] [Abstract][Full Text] [Related]
13. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
Coque TM; Singh KV; Murray BE
J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods.
Hershberger E; Aeschlimann JR; Moldovan T; Rybak MJ
Antimicrob Agents Chemother; 1999 Mar; 43(3):717-21. PubMed ID: 10049300
[TBL] [Abstract][Full Text] [Related]
15. Ceftaroline Plus Ampicillin Against Gram-Positive Organisms: Results from E-Test Synergy Assays.
D'Arezzo S; Mazzarelli A; Venditti C; Nisii C; Petrosillo N; De Giuli C; Vulcano A; Paglia MG; Bordi E; Di Caro A; Taglietti F
Microb Drug Resist; 2017 Jun; 23(4):507-515. PubMed ID: 27526275
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory and bactericidal effects of telithromycin (HMR 3647, RU 56647) and five comparative antibiotics, used singly and in combination, against vancomycin-resistant and vancomycin-susceptible enterococci.
Baltch AL; Smith RP; Ritz WJ; Bopp LH
Chemotherapy; 2001; 47(4):250-60. PubMed ID: 11399861
[TBL] [Abstract][Full Text] [Related]
17. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.
Firsov AA; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
Antimicrob Agents Chemother; 1999 Mar; 43(3):498-502. PubMed ID: 10049257
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of ampicillin/sulbactam against enterococci determined by the time-kill method.
D'Amato RF; Mathew A; Hochstein L; Cleri DJ; Johnson J
Diagn Microbiol Infect Dis; 1989; 12(1):9-11. PubMed ID: 2496949
[TBL] [Abstract][Full Text] [Related]
19. The comparative in vitro activity of clinafloxacin and other antimicrobials against vancomycin-susceptible and vancomycin-resistant enterococci.
Itokazu GS; Nathan C; Hariharan R; Kostman JR; Kabins SA; Weinstein RA
Chemotherapy; 1996; 42(4):235-9. PubMed ID: 8804789
[TBL] [Abstract][Full Text] [Related]
20. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
